Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Ev3 Neurovascular

Approvalsdevice change approved (PMA)14 Oct 2026

Ev3 Neurovascular

14 Oct 2026: Device change approved (PMA) · Onyx™ Liquid Embolic System (Onyx™ LES). Recorded in the openFDA device PMA data.

View the source record

Decided
14 Oct 2026
Device
Onyx™ Liquid Embolic System (Onyx™ LES)
Specialty
Neurology
Type
Supplement (Normal 180 Day Track No User Fee)
Reason
Postapproval Study Protocol
Reference
P030004 S039
Location
Irvine, CA
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Ev3 Neurovascular

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

More in Neurology

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.